Shulman LM
The Parkinson's Disease and Movement Disorders Center, University of Miami School of Medicine, 1501 NW 9th Avenue, Miami, FL 33136, USA.
Curr Treat Options Neurol. 1999 Mar;1(1):14-20. doi: 10.1007/s11940-999-0028-2.
Although dopamine receptor agonists are not simple to use, they are assuming increased importance in the treatment of early and advanced symptoms of Parkinson's disease (PD). The new agonists, pramipexole and ropinirole, are generally adequate without levodopa for early symptoms and carry the hope for a more acceptable profile of long-term side effects. In the patient with advanced disease, all four dopamine agonists significantly augment the response to levodopa, which reduces the problems of motor fluctuations and drug-related dyskinesia. Understanding the common pitfalls when prescribing these drugs will facilitate their safety and efficacy.
尽管多巴胺受体激动剂使用起来并不简单,但它们在帕金森病(PD)早期和晚期症状的治疗中变得越来越重要。新型激动剂普拉克索和罗匹尼罗,对于早期症状而言,通常在不使用左旋多巴的情况下就足够了,并且有望带来更易接受的长期副作用情况。对于晚期疾病患者,所有四种多巴胺激动剂都能显著增强对左旋多巴的反应,从而减少运动波动和药物相关异动症的问题。了解这些药物处方时常见的陷阱将有助于提高其安全性和有效性。